IZIlene H. Zuckerman

Ilene H. Zuckerman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ilene H. Zuckerman has a total of 58 co-authors. Here are the top co-authors by number of shared publications:

  • Bruce Stuart

    Department of Pharmaceutical Health Services Research School of Pharmacy University of Maryland Baltimore Maryland

    4 shared publications
  • C. Daniel Mullins

    Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, MD

    3 shared publications
  • Gail B. Rattinger

    Department of Pharmaceutical Health Services Research School of Pharmacy University of Maryland Baltimore Maryland

    3 shared publications
  • Masayo Sato

    Department of Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore, MD

    3 shared publications
  • Priscilla T. Ryder

    Department of Pharmacy Practice, School of Pharmacy, Butler University, Indianapolis, Indiana, USA

    3 shared publications
  • Amy J. Davidoff

    Yale School of Public Health, New Haven, CT

    2 shared publications

Latest Publications

  • Validation of Disability Status, a Claims-based Measure of Functional Status for Cancer Treatment and Outcomes Studies

    by Amy J. Davidoff, Lisa D. Gardner, Ilene H. Zuckerman, Franklin Hendrick, Xuehua Ke, Martin J. Edelman

    Background: In prior research, we developed a claims-based prediction model for poor patient disability status (DS), a proxy measure for performance status, commonly used by oncologists to summarize patient functional status and assess ability of a patient to tolerate aggressive treatment. In this study, we implemented and validated the DS measure in 4 cohorts of cancer patients: early and advanced non–small cell lung cancers (NSCLC), stage IV estrogen receptor-negative (ER−) breast cancer, and myelodysplastic syndromes (MDS). Data and Methods: SEER-Medicare data (1999–2007) for the 4 cohorts of cancer patients. Bivariate and multivariate logistic regression tested the association of the DS measure with designated cancer-directed treatments: early NSCLC (surgery), advanced NSCLC (chemotherapy), stage IV ER− breast cancer (chemotherapy), and MDS (erythropoiesis-stimulating agents). Treatment model fit was compared across model iterations. Results: In both unadjusted and adjusted results, predicted poor DS was strongly associated with a lower likelihood of cancer treatment receipt in all 4 cohorts [early NSCLC (N=20,280), advanced NSCLC (N=31,341), stage IV ER− breast cancer (N=1519), and MDS (N=6058)] independent of other patient, contextual, and disease characteristics, as well as the Charlson Comorbidity Index. Inclusion of the DS measure into models already controlling for other variables did not significantly improve model fit across the cohorts. Conclusions: The DS measure is a significant independent predictor of cancer-directed treatment. Small changes in model fit associated with both DS and the Charlson Comorbidity Index suggest that unobserved factors continue to play a role in determining cancer treatments.


  • A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes

    by Amy J. Davidoff, Ilene H. Zuckerman, Naimish Pandya, Franklin Hendrick, Xuehua Ke, Arti Hurria, Stuart M. Lichtman, Arif Hussain, Jonathan P.Weiner, Martin J. Edelman


  • Effect of Exposure to Evidence‐Based Pharmacotherapy on Outcomes After Acute Myocardial Infarction in Older Adults

    by Ilene H. Zuckerman, Xianghua Yin, Gail B. Rattinger, Stephen S. Gottlieb, Linda Simoni‐Wastila, Sarah A. Pierce, Ting‐Ying Huang, Rahul Shenolikar, Bruce Stuart

    Objectives: To assess the effect of exposure to evidence‐based medication after hospital discharge for M edicare beneficiaries with acute myocardial infarction ( AMI ). Design: A discrete‐time hazard model was used to estimate time to outcome associated with exposure to four drug classes (angiotensin‐converting enzyme inhibitors ( ACEI s)/angiotensin‐II receptor blockers ( ARB s), beta‐blockers ( BB s), statins, and clopidogrel) used for post‐ AMI secondary prevention of cardiovascular events and mortality. Setting: Medicare administrative data for a 5% random sample of beneficiaries. Participants: Medicare beneficiaries (N = 9,538) hospitalized for an AMI between A pril 1, 2006, and D ecember 31, 2007, who survived for at least 30 days after discharge. The cohort was followed until death or D ecember 31, 2008. Measurements: Time‐varying exposure was measured as proportion of days covered ( PDC ) for each quarter during the follow‐up period. PDC was classified into five categories (0–0.2, 0.2–0.4, 0.4–0.6, 0.6–0.8, 0.8–1.0). Outcomes were mortality and a composite outcome of death or post‐ AMI hospitalization. Results: Over a median follow‐up of 18 months, mean PDC rates ranged from 0.37 (clopidogrel) to 0.50 (statins). When comparing the highest versus lowest categories of exposure, the hazard of the composite outcome was significantly lower for all drug classes except BB s (statins, adjusted hazard ratio (a HR ) = 0.71, ACEI s/ ARB s, a HR = 0.81, clopidogrel, a HR = 0.85, BBs, a HR = 0.93). All four drug classes were significantly associated with reductions in mortality; the magnitude of effect for the mortality outcome was largest for statins and smallest for BB s. Age modified the effect of statins on mortality. Conclusion: Use of evidence‐based medications for secondary prevention after AMI is suboptimal in the M edicare population, and low exposure rates are associated with significantly higher risk for subsequent hospitalization and death.


  • Open Access

    Does an increase in non-antihypertensive pill burden reduce adherence with antihypertensive drug therapy?

    by Ilene H. Zuckerman, Masayo Sato, Gail B. Rattinger, Christopher Zacker, Bruce Stuart

    Objectives: Hypertensive patients often are prescribed multiple medications for their hypertension as well as for other chronic conditions. Poor adherence has been both positively and negatively associated with increasing numbers of medications or required daily doses. We sought to determine whether adherence with antihypertensive drugs changes in response to a change in non-antihypertensive pill burden. Methods: This retrospective cohort analysis used 2006–2007 US MarketScan Medicare Supplemental and Coordination of Benefits administrative data. The study sample comprised 471 359 beneficiaries diagnosed with hypertension. We measured monthly proportion of days covered (PDC) with antihypertensive medications and average number of daily doses with non-antihypertensive drugs (pill burden). We assessed the effect of changes in pill burden on subsequent changes in antihypertensive PDC using difference equations with sensitivity tests for the sign and magnitude of monthly change in pill burden and the presence of physician visits. Key findings: Changes in monthly non-antihypertensive pill burden had essentially no impact on antihypertensive adherence rates for Medicare beneficiaries in retiree health plans. A monthly addition of one non-antihypertensive pill/day resulted in a statistically significant reduction in the following month's antihypertensive medication PDC of approximately one percentage point (−0.98). Similar results were obtained in a 3-month lag model (−0.88). These findings were insensitive to changes in model parameters. Conclusions: while physicians should pay close attention to individual factors that may affect their patients' adherence to antihypertensive medications, our findings indicate that changes in medications used to treat concomitant diseases should have little short-term impact on antihypertensive adherence.


  • The Effect of Dementia on Medication Use and Adherence Among Medicare Beneficiaries With Chronic Heart Failure

    by Gail B. Rattinger, Sarah K. Dutcher, Pankdeep T. Chhabra, Christine S. Franey, Linda Simoni-Wastila, Stephen S. Gottlieb, Bruce Stuart, Ilene H. Zuckerman


  • Chemotherapy Treatment and Survival in Older Women with Estrogen Receptor–Negative Metastatic Breast Cancer: A Population‐Based Analysis

    by Myra Schneider, Ilene H. Zuckerman, Eberechukwu Onukwugha, Naimish Pandya, Brian Seal, Jim Gardner, C. Daniel Mullins

    OBJECTIVES: To investigate the survival benefit associated with chemotherapy receipt in older women with estrogen receptor–negative (ER–) Stage IV breast cancer. DESIGN: Observational, retrospective cohort study using Cox proportional hazards regression to determine effect of chemotherapy on hazard of all‐cause mortality. The two samples were an overall sample (n=1,519) and a propensity score–matched sample (n=580) to control for selection to treatment receipt. Hazard ratios (HRs) and 95% confidence intervals (CIs) were obtained for regression models. SETTING: U.S. women within the National Cancer Institute Surveillance, Epidemiology and End Results cancer registries (SEER) linked to Medicare enrollment and claims database. PARTICIPANTS: Female Medicare beneficiaries aged 66 and older with Stage IV ER– breast cancer diagnosed between 1999 and 2005. MEASUREMENTS: Outcome measure was all‐cause death during the follow‐up period. Survival was measured as time from breast cancer diagnosis until death or last follow‐up date. Information on receipt of chemotherapy, defined as chemotherapy received within 6 months after diagnosis, was obtained from linked Medicare claims. RESULTS: One thousand five hundred nineteen ER– women diagnosed with metastatic breast cancer were identified; 494 (33%) received chemotherapy. Chemotherapy was associated with a statistically significant survival benefit (HR=0.61, 95% CI=0.54–0.70). Age did not modify the survival benefit of chemotherapy. CONCLUSION: Chemotherapy received within 6 months after diagnosis was associated with a 39% lower hazard of death within the time period for the study. These findings reflect chemotherapy use outside of the clinical trial setting and have important clinical and policy implications for the study of treatments in older women with advanced ER– breast cancer.


  • Open Access

    Residential and Health Care Transition Patterns Among Older Medicare Beneficiaries Over Time

    by Masayo Sato, Thomas Shaffer, Alicia I. Arbaje, Ilene H. Zuckerman

    Purpose: To describe annual care transition patterns across residential and health care settings and assess consistency in care transition patterns across years. Design and Methods: This retrospective cohort study used the Medicare Current Beneficiary Survey (2000–2005). The sample comprised beneficiaries aged 65 years and older (N = 57,684 person-years of observation). We defined annual care transition patterns by combining 4 types of settings: C (community), F (facility), S (skilled nursing facility—SNF), and H (hospital). We compared weighted frequencies of transition patterns across years. We counted repeated/multiple transitions that involved movement into hospital and SNF settings and compared them by demographic characteristics. Results: Care transition patterns remained consistent from year to year. Approximately 22% of the study population experienced a transition annually. The most frequent transition pattern was transition to the hospital and back. Care transition patterns were enormously heterogeneous with more than 230 unique patterns; approximately 1 in 4 community-dwelling (∼23%) and most facility-dwelling (∼60%) beneficiaries with at least one transition had a unique transition pattern. Beneficiaries residing in a facility were more likely to undergo multiple transitions to hospitals and SNFs compared with community-dwelling beneficiaries. Implications: The study provides a description of annual care transition patterns across six years. Knowledge of the consistency of care transition patterns may serve as a baseline from which to compare future patterns and aid in designing interventions targeted at specific transitions.


  • Effect of Age on Survival Benefit of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer

    by Ilene H. Zuckerman, Thomas Rapp, Ebere Onukwugha, Amy Davidoff, Michael A. Choti, James Gardner, Brian Seal, C. Daniel Mullins

    OBJECTIVES: To estimate the modifying effect of age on the survival benefit associated with adjuvant chemotherapy receipt in elderly patients with a diagnosis of Stage III colon cancer. DESIGN: Observational, retrospective cohort study using two samples: an overall sample of 7,182 patients to provide externally valid analyses and a propensity score–matched sample of 3,016 patients to provide more internally valid analyses by reducing the presence of treatment endogeneity. An interval‐censored survival model with a complementary log‐log link was used. Hazard ratios and 95% confidence intervals were obtained for all regressions. SETTINGS: Data from the National Cancer Institute's Surveillance, Epidemiology and End Results database and the linked Medicare enrollment and claims database were used. PARTICIPANTS: Selected patients were aged 66 and older and had a diagnosis of Stage III colon cancer. Patients were followed from surgery to time of death or censorship. MEASUREMENTS: The outcome was colon cancer–specific death during the follow‐up period. Receipt of adjuvant chemotherapy was measured according to the presence of a claim for 5‐fluorouracil or leucovorin within 6 months after surgery. RESULTS: All elderly patients had a significant survival benefit associated with adjuvant chemotherapy receipt, although the survival benefit of adjuvant chemotherapy was not uniform across all age groups. CONCLUSION: These findings have important clinical and policy implications for the risk–benefit calculation induced by treatment in older patients with Stage III colon cancer. The results suggest that there is a benefit from chemotherapy, but the benefit is lower with older age.


  • Administrators' Perceptions of Medication Management in Assisted Living Facilities: Results from Focus Groups

    by Priscilla T. Ryder, Melanie Joseph, Marni Zuckerman, Ilene H. Zuckerman

    Objective: Assisted living (AL) residents are vulnerable to adverse events as a result of using numerous medications and frequently need assistance in administering medications. Very little is known, however, about the ways in which medications are managed within this level of care. Design: AL administrators from the metropolitan Baltimore, Maryland area were invited to participate in focus groups to explore issues involved in medication management. Setting and Participants: Four administrators from smaller (15 beds or fewer) and six larger (more than 15 beds) certified AL facilities serving primarily older residents participated. Administrators must have served in their position at least six months. Results: Administrators described interactions with residents, physicians, and pharmacists as well as the issues of state regulations and their enforcement. We uncovered themes concerning the challenges faced in negotiating competing needs of residents, providers, and regulatory bodies. Conclusions: Administrators often feel torn between competing requirements of their position, and they experience some degree of conflict in allowing residents to retain autonomy in the face of demands of family, providers, and regulators. Small-facility administrators especially report being in a position to allow them to monitor residents' medication reactions and needs. Large-facility administrators sometimes find their actions hampered by decisions made at higher (ownership) levels. Administrators want AL facilities to remain at an intermediate level of care, with less stringent regulations than for those for nursing facilities, but would also like more consistency in enforcement of regulations. Qualitative assessment of medication-related issues in AL can help to guide policy in this area. Abbreviations: ADL = Activities of daily living, AL = Assisted living, CMA = Certified medication aide, MAR = Medication administration record, OTC = Over the counter, SNF = Skilled nursing facilities, VA = Veterans Affairs. Consult Pharm 2009;24:513-23.


  • Open Access

    Racial and Ethnic Disparities in the Treatment of Dementia Among Medicare Beneficiaries

    by Ilene H. Zuckerman, Priscilla T. Ryder, Linda Simoni-Wastila, Thomas Shaffer, Masayo Sato, Lirong Zhao, Bruce Stuart

    Objectives. Numerous studies have documented disparities in health care utilization between non-Hispanic White and minority elders. We investigated differences in anti-dementia medication use between non-Hispanic White and minority community-dwelling Medicare beneficiaries with dementia. Methods. Using multivariate analysis with generalized estimating equations, we estimated prevalence ratios (PRs) for anti-dementia medication use by race/ethnicity for 1,120 beneficiaries with dementia from years 2001 through 2003 of the Medicare Current Beneficiary Survey. Results. After adjusting for demographics, socioeconomics, health care access and utilization, comorbidities, and service year, we found that anti-dementia medication use was approximately 30% higher among non-Hispanic Whites compared to other racial/ethnic groups (PR = 0.73, 95% confidence interval [CI] = 0.59, 0.91). As for individual racial/ethnic groups, prevalence disparities remained significant for non-Hispanic Blacks (PR = 0.75, 95% CI = 0.57, 0.99) and non-Hispanic others (PR = 0.50, 95% CI = 0.26, 0.96) but were attenuated for Hispanics (PR = 0.84, 95% CI = 0.59, 1.20). Discussion. Results provide evidence that racial/ethnic disparities in utilization of drugs used to treat dementia exist and are not accounted for by differences in demographic, economic, health status, or health utilization factors. Findings provide a foundation for further research that should use larger numbers of minority patients and consider dementia type and severity, access to specialty dementia care, and cultural factors.